NCT04549207 2025-11-28Comparing Continuation or De-escalation of Bone Modifying Agents (BMA) in Patients Treated for Over 2 Years for Bone Metastases From Either Breast or Castration-resistant Prostate CancerOttawa Hospital Research InstitutePhase 4 Active not recruiting240 enrolled